HK Stock Market Move | IMMUNEONCO-B(01541) rose more than 6% at the close of trading, and the IND application for IMM0306 primary Sjogren's syndrome was officially approved.

IMMUNEONCO-B (01541) rose more than 6% at the end of the trading day, up 5.41% to 3.7 Hong Kong dollars as of the press release, with a turnover of 2.3126 million Hong Kong dollars. On the news front, Yimingonc announced recently that its self-developed drug, Amuri Fu Pu (IMM0306), for the indication of primary Sjogren's syndrome (pSS), has officially received approval for new drug clinical trial application from the China National Medical Products Administration. This development marks another important breakthrough in Yimingonc's innovative drug research and development in the field of autoimmune diseases. The approval of the pSS indication IND this time is another important achievement of Yimingonc's "comprehensive advancement of its self-immune pipeline" strategy. Clinical studies for multiple major indications such as systemic lupus erythematosus (SLE) and IgG4-related diseases (IgG4-RD) for IMM0306 are steadily progressing, with clinical data for the Ib phase of SLE to be presented at the 2026 EULAR meeting. In recent years, leveraging the strong scalability of the "mAb-Trap" technology platform, Yimingonc has built a rich and deep product pipeline in the field of autoimmune diseases.